ARGLU1 (Arginine and Glutamate Rich1) is a newly identified nuclear protein with suggested multifunctional roles that may be implicated in the pathogenesis and therapeutic resistance of glioma, the most common primary malignant brain tumor. The high heterogeneity and treatment resistance of gliomas pose central challenges in clinical management. ARGLU1 has been implicated in maintaining genomic stability and may contribute to tumor progression by regulating RNA splicing and DNA damage repair pathways. This review systematically summarizes the structural and functional features of ARGLU1 and discusses its potential molecular mechanisms in glioma. These include its influence on the spliceosome assembly, alternative splicing events, and key DNA repair pathways such as homologous recombination (HR) and Fanconi anemia (FA). Furthermore, it discusses the hypothesis that ARGLU1 may enhance DNA repair capacity and thereby influence glioma resistance to temozolomide (TMZ) and radiotherapy. Targeting ARGLU1 may offer a strategy to overcome this resistance. Finally, the review outlines current research limitations and future directions, aiming to provide a new theoretical foundation for the precision treatment of glioma.

Background: This study aims to elucidate the relationship between serum sodium and the risk of sepsis-associated delirium (SAD), with particular emphasis on the critical threshold of 138.4 mmol/L. Methods: The retrospective study utilized data from the MIMIC-IV database. The analysis focused on serum sodium concentrations measured within the first 24 h of ICU admission. The association between sodium levels and the risk of delirium was assessed using restricted cubic spline (RCS) analysis and multivariable logistic regression. Subgroup analyses and propensity score matching (PSM) were used to mitigate potential confounding factors. Results: A total of 7356 septic patients were included, with 1861 (25.3%) developing delirium. RCS analysis revealed a significant non-linear relationship between sodium levels and delirium risk, with a threshold at 138.4 mmol/L. Sodium levels ≤ 138.4 mmol/L were associated with a reduced risk of delirium (OR 0.97, 95% CI: 0.95–0.99, p = 0.041), while levels > 138.4 mmol/L significantly increased the risk of delirium (OR 1.08, 95% CI: 1.06–1.11, p < 0.001). After PSM, hypernatremia was associated with a higher delirium incidence than hyponatremia (55.00% vs. 36.67%, p = 0.044) and remained an independent risk factor for delirium in logistic regression (OR 2.89, 95% CI 1.17–7.18, p = 0.022). Conclusions: This study identified a non-linear, threshold-dependent association between serum sodium and delirium susceptibility in septic patients, with 138.4 mmol/L as a critical tipping point. Hypernatremia emerged as a more potent risk factor for delirium compared to hyponatremia. These findings underscore the importance of sodium management in septic patients and suggest that serum sodium may serve as a potential biomarker for predicting neuropsychiatric outcomes in sepsis.